Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

998
Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
998
Overview of Protein Metabolism01:21

Overview of Protein Metabolism

4.6K
Proteins are broken down into amino acids during digestion. Unlike fats and carbohydrates, which are stored for later use, proteins are not. Instead, amino acids are either used to produce ATP through oxidation or contribute to the creation of new proteins for the growth and repair of the body. Any surplus amino acids from the diet are converted into glucose or triglycerides rather than excreted.
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
4.6K
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

59
Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
59
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

322
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
322
Allosteric Proteins-ATCase01:19

Allosteric Proteins-ATCase

6.9K
Binding sites linkages can regulate a protein's function.  For example, enzyme activity is often regulated through a feedback mechanism where the end product of the biochemical process serves as an inhibitor.
Aspartate transcarbamoylase (ATCase) is a cytosolic enzyme that catalyzes the condensation of L-aspartate and carbamoyl phosphate to  N-carbamoyl-L-aspartate. This reaction is the first step in pyrimidine biosynthesis. UTP and CTP, the end products of the pyrimidine synthesis...
6.9K
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

595
Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
595

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The clinical utility of functional testing in fibroblasts to diagnose primary mitochondrial disease.

medRxiv : the preprint server for health sciences·2026
Same author

From genotype to outcome: Zygosity-specific insights in 63 cases of CLPB-related mitochondrial disease.

Molecular genetics and metabolism·2026
Same author

Current Treatment Modalities for Urea Cycle Disorders.

Paediatric drugs·2025
Same author

The PKU Patient Registry: Development of a patient-driven registry and initial outcomes.

Molecular genetics and metabolism·2025
Same author

Phenylketonuria in adults: we know plenty, but there is much more to learn.

The American journal of clinical nutrition·2025
Same author

Characterization of Factors Associated With Death in Deceased Patients With Mitochondrial Disorders: A Multicenter Cross-Sectional Survey.

Neurology·2025

Related Experiment Video

Updated: Mar 23, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K

Phenylketonuria (PKU): A problem solved?

Christine S Brown1, Uta Lichter-Konecki2

  • 1National PKU Alliance, Tomahawk, WI 54487, United States.

Molecular Genetics and Metabolism Reports
|March 26, 2016
PubMed
Summary

Phenylketonuria (PKU) patients struggle with high blood phenylalanine (Phe) levels, especially adults. Many desire new treatments for better diet flexibility, mental health, and easier administration, preferably oral.

Keywords:
ACMG, American College of Medical Genetics and GenomicsNPKUA, National PKU AlliancePAH, phenylalanine hydroxylasePKU, phenylketonuriaPhe, phenylalaninePhenylalaninePhenylalanine hydroxylase deficiencyPhenylketonuria

More Related Videos

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K

Related Experiment Videos

Last Updated: Mar 23, 2026

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring
07:35

Use of Ultra-high Field MRI in Small Rodent Models of Polycystic Kidney Disease for In Vivo Phenotyping and Drug Monitoring

Published on: June 23, 2015

12.1K
Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes
15:43

Assessment of Mitochondrial Functions and Cell Viability in Renal Cells Overexpressing Protein Kinase C Isozymes

Published on: January 7, 2013

18.7K
Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases
09:13

Author Spotlight: Identifying Compensatory Pathways in Malaria Parasites Containing Hypomorphic Allele of Essential Protein Kinases

Published on: November 22, 2024

1.9K

Area of Science:

  • Metabolic disorders
  • Genetics and genomics
  • Patient-reported outcomes

Background:

  • Phenylketonuria (PKU) is a rare metabolic disorder causing phenylalanine (Phe) accumulation.
  • Untreated PKU leads to severe physiological, neurological, and intellectual impairments.
  • Effective management often involves strict dietary Phe restriction.

Purpose of the Study:

  • To assess the current health status of PKU patients.
  • To gauge patient interest in novel PKU treatments.
  • To understand patient preferences for PKU therapy administration and outcomes.

Main Methods:

  • A survey was distributed to National PKU Alliance (NPKUA) members.
  • Data collected included blood Phe levels, management challenges, and treatment desires.
  • Respondents' demographic information (age) was analyzed in relation to outcomes.

Main Results:

  • Less than half (46.7%) of 625 respondents met recommended blood Phe levels (<360 μmol/L).
  • Adults had significantly higher blood Phe levels (61.5%) compared to younger individuals (25.5%).
  • Over half (51.7%) reported difficulties managing PKU, desiring improved diet, mental health, and oral therapies.

Conclusions:

  • Current PKU management is suboptimal for many patients, particularly adults.
  • Patients strongly desire new therapies offering dietary freedom and improved quality of life.
  • Patient preferences for oral administration and specific outcomes should guide PKU treatment development.